3 Undervalued Managed Health care Stocks for Wednesday, July 24
Discover the top 3 undervalued Managed Health care stocks for Wednesday, July 24 based on AAII’s Stock Grades.Jenna Brashear
Stock Evaluator: Interpace Biosciences, Inc. (IDXG)
Interpace Biosciences, Inc. IDXG
$1.52
-0.09
-5.42%
August 21, 2026 3:01:29 PM
EST
Volume: 9,829
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Commentary & Analysis
3 Undervalued Managed Health care Stocks for Thursday, May 23
Discover the top 3 undervalued Managed Health care stocks for Thursday, May 23 based on AAII’s Stock Grades.Jack Gilleland
3 Undervalued Managed Health care Stocks for Tuesday, April 23
Discover the top 3 undervalued Managed Health care stocks for Tuesday, April 23 based on AAII’s Stock Grades.Grace Malone
3 Undervalued Managed Health care Stocks for Wednesday, February 21
Discover the top 3 undervalued Managed Health care stocks for Wednesday, February 21 based on AAII’s Stock Grades.Eunice Kim
3 Undervalued Managed Health care Stocks for Wednesday, January 10
Discover the top 3 undervalued Managed Health care stocks for Wednesday, January 10 based on AAII’s Stock Grades.Jack Gilleland
Financial Summary
| Share Statistics | IDXG | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $42.2 | $1,968.0 | 14% |
|
| Shares Out (Mil) | 27.7 | 77.7 | 35% |
|
| Institutional Ownership | 13.0% | 86.6% | 7% |
|
| Float (Mil) | 3.5 | 52.1 | 9% |
|
| Beta | 0.61 | 0.75 | 36% |
|
| Avg Daily Volume (000s) | 14 | 612 | 18% |
|
| Price Change (52-week) |
69.2% | 79.8% | 85% |
|
| Growth | IDXG | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.6% | 10.9% | 29% |
|
| Net Income (5yr) | 24.0% | (1.6%) | 79% |
|
| EPS (5yr) | 16.2% | 0.3% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (1.6%) | (17.9%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IDXG | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $1,504 | 17% |
|
| Net Income (TTM) (Mil) | $24 | $28 | 50% |
|
| EPS (TTM) | $1.673 | $0.200 | 68% |
|
| Operating Cash Flow (TTM) (Mil) | $5 | $162 | 36% |
|
| Net Cash Flow (TTM) (Mil) | na | $9 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $338 | 15% |
|
| Enterprise Value (Q1) (Mil) | $43 | $2,416 | 15% |
|
| Valuation | IDXG | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.81 | 2.82 | 46% |
|
| P/E | 1.7 | 26.0 | 1% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 0.1 | 1.1 | 3% |
|
| Ratios | IDXG | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.7% | 27.8% | 76% |
|
| Net Margin | 67.6% | 1.2% | 98% |
|
| ROA | 104.3% | 2.2% | 100% |
|
| ROE | 221.9% | 7.2% | 98% |
|
| Liabilities to Assets | 32.7% | 58.6% | 24% |
|
| F-Score | 6 | 5 | 67% |
|
Interpace Biosciences, Inc. did not pass any screens on 8/21/2026.
